Quotient Wealth Partners LLC Grows Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Quotient Wealth Partners LLC lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 98.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,649 shares of the biopharmaceutical company’s stock after purchasing an additional 4,290 shares during the period. Quotient Wealth Partners LLC’s holdings in Bristol-Myers Squibb were worth $489,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Alliance Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at $237,000. Benedict Financial Advisors Inc. raised its stake in Bristol-Myers Squibb by 1.3% during the fourth quarter. Benedict Financial Advisors Inc. now owns 66,123 shares of the biopharmaceutical company’s stock valued at $3,740,000 after buying an additional 817 shares in the last quarter. Empowered Funds LLC lifted its holdings in Bristol-Myers Squibb by 575.9% during the 4th quarter. Empowered Funds LLC now owns 293,943 shares of the biopharmaceutical company’s stock worth $16,625,000 after buying an additional 250,451 shares during the last quarter. Forbes J M & Co. LLP increased its holdings in shares of Bristol-Myers Squibb by 34.7% in the 4th quarter. Forbes J M & Co. LLP now owns 10,810 shares of the biopharmaceutical company’s stock valued at $611,000 after acquiring an additional 2,783 shares during the last quarter. Finally, D Orazio & Associates Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $208,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and boosted their target price for the company from $63.00 to $70.00 in a research note on Monday, December 16th. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research note on Friday. Sanford C. Bernstein assumed coverage on shares of Bristol-Myers Squibb in a research note on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price target on the stock. Bank of America reissued a “neutral” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Finally, Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Stock Down 0.8 %

NYSE BMY opened at $56.96 on Monday. The company has a market capitalization of $115.51 billion, a P/E ratio of -12.89, a PEG ratio of 2.13 and a beta of 0.45. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.10. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The company’s 50 day simple moving average is $57.56 and its 200 day simple moving average is $53.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%. Equities research analysts expect that Bristol-Myers Squibb will post 6.75 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were issued a $0.62 dividend. The ex-dividend date was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.35%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.